- Home
- BFRG vs BCAB Comparison
BFRG vs BCAB Comparison
Compare BFRG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRG | BCAB |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | 17 | 41 |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BFRG | BCAB |
|---|---|---|
| Price | $0.89 | $4.46 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 26.9M | 868.2K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $0.12 |
| 52 Week High | $2.12 | $6.52 |
Technical Indicators
Market Signals| Indicator | BFRG | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 79.81 |
| Support Level | $0.59 | $0.36 |
| Resistance Level | $1.20 | N/A |
| Average True Range (ATR) | 0.24 | 0.28 |
| MACD | 0.00 | 0.51 |
| Stochastic Oscillator | 26.66 | 68.60 |
Price Performance
Historical ComparisonAbout BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.